Clinical trials: Hidradenitis
Hidradenitis Suppurativa (HS)
Hidradenitis Suppurativa Wound Care
The objective of this case series is to monitor time and outcome of healing of wounds associated with HS using Endoform [ovine forestomach], Hydrofera Blue [methylene blue and gentian violet], and Hypafix tape.
- Trial name
- NCT04354012
- Testing
- methylene blue, gentian violet, and ovine forestomach wound dressings
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University Health Sciences
Hidradenitis Suppurativa (Acne Inversa)
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to…
- Trial name
- NCT02421172
- Testing
- CJM112
- Where
- 16 sites in United States, Denmark and 3 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa
The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER (OLE) (NCT01635764)
- Testing
- adalimumab
- Volunteers
- 508 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NOVA (NCT03628924)
- Testing
- Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3
- Where
- 45 sites in United States, Canada and 4 more
- Volunteers
- 184 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the clinical efficacy of bermekimab in participants with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- LYRA (NCT04988308)
- Testing
- Bermekimab, Adalimumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 151 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa
A Study of Bermekimab in Patients With Hidradenitis Suppurativa
Phase 2 study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa.
- Trial name
- NCT03512275
- Testing
- Bermekimab Monoclonal Antibody 400 mg
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa (HS)
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or study 1368-0100).
- Trial name
- NCT06241573
- Testing
- Spesolimab
- Where
- 36 sites in United States, Argentina and 12 more
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER I (NCT01468207)
- Testing
- adalimumab
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
- Trial name
- NCT03248531
- Testing
- Bimekizumab, Adalimumab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 90 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNRISE (NCT03713632)
- Testing
- Secukinumab
- Where
- 108 sites in United States, Argentina and 30 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER II (NCT01468233)
- Testing
- adalimumab
- Volunteers
- 326 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT03607487
- Testing
- INCB054707
- Where
- 13 sites in Canada, Denmark and 1 more
- Volunteers
- 35 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD I (NCT04242446)
- Testing
- Bimekizumab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 505 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa
This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNSHINE (NCT03713619)
- Testing
- secukinumab
- Where
- 111 sites in United States, Argentina and 27 more
- Volunteers
- 544 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens…
- Trial name
- NCT04179175
- Testing
- secukinumab
- Where
- 191 sites in United States, Argentina and 36 more
- Volunteers
- 702 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa, Acne Inversa
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other…
- Conditions
- Hidradenitis Suppurativa, Acne Inversa, Suppurative Hidradenitis
- Trial name
- NCT04019041
- Testing
- bermekimab
- Where
- 33 sites in United States
- Volunteers
- 153 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis…
- Trial name
- NCT05322473
- Testing
- Sonelokimab (M1095), Adalimumab
- Where
- 57 sites in United States, Bulgaria and 5 more
- Volunteers
- 234 people
- Sponsor
- MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa, Surgical Wound
Wet-to-dry vs Petrolatum & Non-stick Dressings After Hidradenitis Suppurativa Surgery
Hidradenitis suppurativa (HS) is a chronic, severe, inflammatory skin disease associated with pain, drainage, odor, and disability characterized by recurring abscesses, nodules, and tunneling sinuses in intertriginous locations…
- Trial name
- NCT05194969
- Testing
- Wet-to-Dry Dressings, Petrolatum with Non-Stick Gauze
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of North Carolina, Chapel Hill
Hidradenitis Suppurativa
Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa
This study evaluates the effect of hypertonic saline 23.4% injection in fistulas or sinus tracts in adult patients with hidradenitis suppurativa.
- Trial name
- NCT02805595
- Testing
- 23.4% Hypertonic saline
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hidradenitis Suppurativa
A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
The primary objective of this study is to assess the safety and efficacy of risankizumab 180 mg and 360 mg versus placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adult…
- Trial name
- DETERMINED 1 (NCT03926169)
- Testing
- Risankizumab
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 243 people
- Sponsor
- AbbVie